Amid a third-quarter earnings season that has been a mixed bag of beats and misses for drug/biotech companies, today’s article highlights five drug/biotech stocks that appear poised to deliver a positive earnings surprise in their upcoming quarterly results, as they all have a combination that has been shown to increase the odds of an earnings beat by as much as 70%. For these five drug/biotech stocks, CLICK HERE.